In this video, Fool.com health care analysts David Williamson and Max Macaluso discuss Gilead, Amarin, and Cyclacel's intraday pops of more than 5%. One reported excellent earnings, another is subject to buyout rumors, and a third continues its recent winning streak. Watch and find out what this means for these stocks, their competitors, and investors.
Gilead, Amarin, and Cyclacel are all up over 5%
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid
